Drug Profile
Research programme: inhaled dry powder respiratory therapeutics - Merck/MicroDose Therapeutx
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (Inhalation, Powder)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries